Is EXAGEN INC. (XGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 30.9% / 30% | 29.6% / 30% | 10.5% / 30% | 1.38% / 5% | ✗ NOT HALAL |
| DJIM | 30.9% / 33% | 29.6% / 33% | 10.5% / 33% | 1.38% / 5% | ✓ HALAL |
| MSCI | 51.5% / 33% | 49.3% / 33% | 17.5% / 33% | 1.38% / 5% | ✗ NOT HALAL |
| S&P | 30.9% / 33% | 29.6% / 33% | 10.5% / 33% | 1.38% / 5% | ✓ HALAL |
| FTSE | 51.5% / 33% | 49.3% / 33% | 17.5% / 50% | 1.38% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 58.3% | |
| Operating Margin | -29.9% | |
| Net Margin | -30.0% | |
| Return on Equity (ROE) | -147.8% | |
| Return on Assets (ROA) | -17.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$14M |
| Free Cash Flow | -$14M |
| Total Debt | $26M |
| Debt-to-Equity | 158.6 |
| Current Ratio | 3.5 |
| Total Assets | $58M |
Price & Trading
| Last Close | $2.79 |
| 50-Day MA | $3.55 |
| 200-Day MA | $7.36 |
| Avg Volume | 492K |
| Beta | 1.9 |
|
52-Week Range
$2.63
| |
About EXAGEN INC. (XGN)
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is EXAGEN INC. (XGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), EXAGEN INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is EXAGEN INC.'s debt ratio?
EXAGEN INC.'s debt ratio is 30.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 51.5%.
What are EXAGEN INC.'s key financial metrics?
EXAGEN INC. has a market capitalization of $64M, and revenue of $67M. The company maintains a gross margin of 58.3% and a net margin of -30.0%. Return on equity stands at -147.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.